These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 27272070)

  • 21. Δ9-Tetrahydrocannabinol-like effects of novel synthetic cannabinoids found on the gray market.
    Gatch MB; Forster MJ
    Behav Pharmacol; 2015 Aug; 26(5):460-8. PubMed ID: 26061356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conditioned Taste Avoidance Drug Discrimination Procedure: Assessments and Applications.
    Riley AL; Clasen MM; Friar MA
    Curr Top Behav Neurosci; 2018; 39():297-317. PubMed ID: 27221624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nicotine pre-treatment reduces sensitivity to the interoceptive stimulus effects of commonly abused drugs as assessed with taste conditioning paradigms.
    Loney GC; Meyer PJ
    Drug Alcohol Depend; 2019 Jan; 194():341-350. PubMed ID: 30472574
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Separate and combined effects of the GABA reuptake inhibitor tiagabine and Δ9-THC in humans discriminating Δ9-THC.
    Lile JA; Kelly TH; Hays LR
    Drug Alcohol Depend; 2012 Apr; 122(1-2):61-9. PubMed ID: 21975195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Delta(9)-tetrahydrocannabinol in C57BL/6J mice.
    McMahon LR; Ginsburg BC; Lamb RJ
    Psychopharmacology (Berl); 2008 Jul; 198(4):487-95. PubMed ID: 17673980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of an inhaled toluene drug discrimination in mice: effect of exposure conditions and route of administration.
    Shelton KL; Slavova-Hernandez G
    Pharmacol Biochem Behav; 2009 Jun; 92(4):614-20. PubMed ID: 19268500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adverse Reactions to Illicit Drugs (Marijuana, Opioids, Cocaine) and Alcohol.
    Decuyper II; Armentia A; Martín-Armentia B; Almuzara AC; Ebo DG; Brucker HA
    J Allergy Clin Immunol Pract; 2021 Aug; 9(8):3006-3014. PubMed ID: 33965592
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dopaminergic augmentation of delta-9-tetrahydrocannabinol (THC) discrimination: possible involvement of D(2)-induced formation of anandamide.
    Solinas M; Tanda G; Wertheim CE; Goldberg SR
    Psychopharmacology (Berl); 2010 Apr; 209(2):191-202. PubMed ID: 20179908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discriminative stimulus and subject-rated effects of methamphetamine, d-amphetamine, methylphenidate, and triazolam in methamphetamine-trained humans.
    Sevak RJ; Stoops WW; Hays LR; Rush CR
    J Pharmacol Exp Ther; 2009 Mar; 328(3):1007-18. PubMed ID: 19104030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of psychotic symptoms in substance users: a comparison across substances.
    Smith MJ; Thirthalli J; Abdallah AB; Murray RM; Cottler LB
    Compr Psychiatry; 2009; 50(3):245-50. PubMed ID: 19374969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discriminative stimulus, subject-rated and cardiovascular effects of cocaine alone and in combination with aripiprazole in humans.
    Lile JA; Stoops WW; Glaser PE; Hays LR; Rush CR
    J Psychopharmacol; 2011 Nov; 25(11):1469-79. PubMed ID: 20952456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rimonabant-induced Delta9-tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs.
    Stewart JL; McMahon LR
    J Pharmacol Exp Ther; 2010 Jul; 334(1):347-56. PubMed ID: 20375197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Behavioral pharmacology of designer cathinones: a review of the preclinical literature.
    Gregg RA; Rawls SM
    Life Sci; 2014 Feb; 97(1):27-30. PubMed ID: 24231450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Agonist efficacy, drug dependence, and medications development: preclinical evaluation of opioid, dopaminergic, and GABAA-ergic ligands.
    Bergman J; France CP; Holtzman SG; Katz JL; Koek W; Stephens DN
    Psychopharmacology (Berl); 2000 Dec; 153(1):67-84. PubMed ID: 11255930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discriminative Stimulus Effects of Abused Inhalants.
    Shelton KL
    Curr Top Behav Neurosci; 2018; 39():113-139. PubMed ID: 27714629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Locomotor activity and discriminative stimulus effects of a novel series of synthetic cathinone analogs in mice and rats.
    Gatch MB; Dolan SB; Forster MJ
    Psychopharmacology (Berl); 2017 Apr; 234(8):1237-1245. PubMed ID: 28210779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genes and pathways co-associated with the exposure to multiple drugs of abuse, including alcohol, amphetamine/methamphetamine, cocaine, marijuana, morphine, and/or nicotine: a review of proteomics analyses.
    Wang J; Yuan W; Li MD
    Mol Neurobiol; 2011 Dec; 44(3):269-86. PubMed ID: 21922273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interactions between Delta(9)-tetrahydrocannabinol and mu opioid receptor agonists in rhesus monkeys: discrimination and antinociception.
    Li JX; McMahon LR; Gerak LR; Becker GL; France CP
    Psychopharmacology (Berl); 2008 Aug; 199(2):199-208. PubMed ID: 18470505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exploring drug-target interaction networks of illicit drugs.
    Atreya RV; Sun J; Zhao Z
    BMC Genomics; 2013; 14 Suppl 4(Suppl 4):S1. PubMed ID: 24268016
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Wastewater analysis reveals regional variability in exposure to abused drugs and opioids in Finland.
    Vuori E; Happonen M; Gergov M; Nenonen T; Järvinen A; Ketola RA; Vahala R
    Sci Total Environ; 2014 Jul; 487():688-95. PubMed ID: 24275228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.